{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 82 of 122', 'maximum severity at the OLFC and by treatment group. The Cochran-Mantel-Haenszel', 'statistics with equally spaced scores (row mean score differences statistic) stratified by', 'country will be used to test for a treatment difference.', 'The proportion of subjects successfully completing the RWPC with no or mild symptoms', 'after approximately 13 months of AR101 treatment will be assessed by presenting the', 'response rate and the associated 95% CI using an exact Clopper-Pearson CI.', 'The maximum severity of symptoms during the RWPC after approximately 13 months of', 'AR101 treatment in eligible subjects who consented to the RWPC will be assessed by', 'tabulating the number and percentage of subjects by maximum severity.', 'Full details will be provided in the statistical analysis plan.', '10.8 Analysis of Safety', 'All safety analyses will be performed using the safety population. Safety data will be listed', 'and summarized by treatment received. Descriptive statistics will be used.', 'Safety data will be collected from signed informed consent/assent through early', 'discontinuation or study exit, and through at least 30 days after early discontinuation or study', 'exit for subjects with unresolved adverse events or through at least 6 months after early', 'discontinuation or study exit for subjects with GI adverse events of interest.', 'Adverse events will be classified by system organ class and coded to preferred term using the', 'Medical Dictionary for Regulatory Activities (MedDRA). Adverse events will be classified', 'by severity using the CoFAR grading system for allergic reactions, EAACI guidelines for', 'anaphylaxis, and CTCAE for all other adverse events (Section 8.4).', 'Summaries of the safety of AR101 treatment and standard of care alone during the study will', 'include the following:', 'Overall summary of adverse events', 'Incidence of all nonserious and serious adverse events', 'Incidence of adverse events by severity grade', 'AR101 treatment only:', '-', 'Incidence of adverse events during up-dosing and maintenance', '-', 'Incidence of adverse events with onset < 90 minutes after AR101 dosing at the', 'study site', '-', 'Incidence and severity of treatment-related adverse events', '-', 'Incidence of treatment-related adverse events during up-dosing and maintenance', '-', 'Incidence of treatment-related adverse events with onset < 90 minutes after', 'AR101 dosing at the study site']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 83 of 122', '-', 'Incidence of dose modifications', '-', 'Exposure-adjusted event rates for the most frequent treatment-related adverse', 'events (ie, adverse events in > 5% of the safety population)', 'Exposure-adjusted event rates for the most frequent adverse events (ie, adverse events', 'in > 5% of the safety population)', 'Incidence of early treatment discontinuation due to adverse events and due to chronic', 'or recurrent GI adverse events', 'Separate summaries will be presented for anaphylaxis, allergic reaction adverse', 'events, use of epinephrine, and accidental/nonaccidental food allergen exposure', 'Adverse events with onset before the first dose of AR101 treatment (or on day 1 for standard', 'of care alone) will be listed only.', 'All medications will be coded using the World Health Organization Drug Dictionary', '(WHO-DD). Medications will be listed and summarized by Anatomical Therapeutic', 'Chemical (ATC) classification system level 1 and preferred name.', 'Prior and concomitant medications, excluding rescue medications, will be', 'summarized separately by ATC class, preferred name, and treatment.', 'Rescue medications used during screening, initial dose escalation, up-dosing,', 'maintenance, and overall (including all rescue medications reported on the case report', 'form) will be summarized by ATC class, preferred name, and treatment received.', 'All prior, concomitant, and rescue medications will be listed by subject.', 'Summary statistics will be provided for the ACT, lung function data, and laboratory data if', 'relevant. These data will also be listed by subject.', 'Full details for the safety analyses will be provided in the statistical analysis plan.', '10.9 Other Analyses', 'Additional endpoints will be assessed over the course of the study as follows:', 'Changes from baseline in TNSS scores in subjects with pre-existing allergic rhinitis', 'Changes from baseline in SCORAD scores in subjects with pre-existing atopic', 'dermatitis', 'Changes in peanut SPT mean wheal diameters', 'Full details for these analyses will be provided in the statistical analysis plan.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 84 of 122', '11 STUDY COMMITTEES AND COMMUNICATIONS', 'As this is open-label, an internal safety monitoring committee (SMC) will be established to', 'monitor the study for safety. The committee will meet at least quarterly to review the study', 'safety data in accordance with the SMC charter.', '12 LABORATORY REQUIREMENTS', '12.1 Clinical Laboratory Tests', 'Clinical laboratory tests (hematology, immunology) will be performed at screening and at', 'unscheduled visits as necessary. Samples will be stored until the specified analyses are', 'completed and then will be destroyed in accordance with standard laboratory practice and', 'applicable local regulations.', 'A list of the required clinical laboratory tests and other evaluations is provided in Table 20.', 'All samples for laboratory analysis must be collected, prepared, labeled, and shipped', 'according to laboratory requirements.', 'All clinical laboratory tests will be performed by a central laboratory unless otherwise', 'specified. The central laboratory reference ranges will be used. Eligibility at screening will', 'be based on central laboratory assessments. A local clinical laboratory may be used to assess', 'samples at unscheduled visits or urgent care to evaluate an adverse event. Central laboratory', 'samples should also be obtained whenever possible during unscheduled visits. No local', 'laboratory data will be entered into the study database.', 'Additional details are provided in the laboratory manual.', 'Table 20: Clinical Laboratory Tests', 'Hematology', 'Immunology', 'Other', 'Red blood cell count', 'Total immunoglobulin (Ig) E', 'Pregnancy test (serum at', 'Hemoglobin', 'screening; urine thereafter) for all', 'Hematocrit', 'Peanut-specific IgE and', 'females of childbearing potential', 'Platelet count', 'components (Ara h 1, Ara h 2,', 'Ara h 3, Ara h 8, Ara h 9)', 'White blood cell count with', 'differential (percent and absolute)', 'Total neutrophils', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 85 of 122', '12.2 Basophil Activation Test', 'Collection of blood samples for basophil activation tests will be performed according to the', 'schedules of activities. The B\u00fchlmann Flow CAST assay uses flow cytometry to measure', 'CD63 upregulation, which is a marker of basophil activation in IgE-mediated responses to', 'peanut. The assay is conducted in whole blood treated with EDTA and tested within 24 to', '48 hours of collection.', '13 INVESTIGATOR AND ADMINISTRATIVE REQUIREMENTS', 'The sponsor must confirm that a study site is activated before an investigator enrolls subjects', 'in the study, and the following documents must be available:', 'Fully executed clinical trial agreement', 'Investigator-signed protocol signature page', 'Investigator-signed acknowledgment of receipt of the current investigator brochure', 'EC and regulatory authority approval letter', 'EC-approved informed consent and assent forms', 'Additional documents as necessary per local requirements', 'If an investigator changes during the course of the study, the sponsor and any local regulatory', 'authorities, as applicable, must first approve the change of investigator and the new', 'investigator must provide the sponsor all of the relevant documents listed above.', 'The sponsor personnel or representatives may visit the study site, if necessary, before', 'initiation of the study to review information with study site personnel about protocol', 'requirements pertaining to the study treatment, case report forms, monitoring, serious adverse', 'event reporting, and other relevant information.', '13.1 Ethics', '13.1.1 Ethics Committee', 'Before initiating the study, the sponsor will obtain confirmation from the EC that the EC is', 'properly constituted and compliant with all requirements and local regulations.', 'The sponsor will provide the EC with all appropriate material, such as the protocol, current', 'investigator brochure, site-specific informed consent/assent form, and other written', 'information provided to the subjects. The study will not be initiated until the appropriate EC', 'and regulatory authority approval is obtained in writing for all required documentation, and', 'copies are received by the sponsor.', 'EC and regulatory authority approval will be obtained for any substantial protocol', 'amendments and informed consent/assent revisions before implementing the changes. The', 'investigator or sponsor will provide appropriate reports on the progress of the study to the']", "completion": ""}